Xeris Biopharma(US:XERS) ZACKS·2024-11-08 14:10Group 1 - Xeris Biopharma reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of 33.33% [1] - The company posted revenues of $54.27 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 5.09%, and showing an increase from $48.32 million year-over-year [2] - Xeris Biopharma shares have increased approximately 43% since the beginning of the year, outperforming the S&P 500's gain of 25.2% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $52.86 million, and for the current fiscal year, it is -$0.40 on revenues of $193.2 million [7] - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8]